ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0403

Comparing Domains Reported by Patients and Other Collaborators in CNO and SAPHO: A Qualitative Study and Scoping Review Using the OMERACT Process

Melissa Oliver1, susan Thornhill2, Beverley Shea3, Jonathan Akikusa2, Christian Hedrich4, Philip Mease5 and Yongdong (Dan) Zhao6, and OMERACT CNO & SAPHO Working Group, 1Indiana University, Indianapolis, IN, 2Royal Children's Hospital, Parkville, Victoria, Australia, 3Ottawa Hospital Research Institute, Ottawa, ON, Canada, 4University of Liverpool, Liverpool, United Kingdom, 5Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, 6University of Washington, Redmond, WA

Meeting: ACR Convergence 2024

Keywords: OMERACT, Outcome measures, Pediatric rheumatology

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Pediatric Rheumatology – Clinical Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Disease outcome measures for chronic nonbacterial osteomyelitis (CNO) & Synovitis, Acne, Pustulosis, Hyperostosis and Osteitis (SAPHO) have been proposed and reported but have lacked input and consensus-based confirmation from collaborators other than physicians.  OMERACT methodology has been well established to develop core domain sets and corresponding instruments for rheumatic diseases. We aimed to identify candidate domains for a core domain set for patients with CNO & SAPHO following OMERACT filter 2.2.

Methods: A scoping review and qualitative research were conducted. The scoping review (SR) was performed by providers using OVID, PubMed, and Google Scholar. Qualitative research consisted of five virtual focus groups from North America, Europe and Asia and four online discussion board groups from Australia and New Zealand. Participants were parents, pediatric patients, adult patients, physicians, a physical therapist and an industry representative. Virtual focus groups (FG) were conducted with a set of questions for participants. Online discussion boards (ODB) used word- or picture-prompted questions to solicit comprehensive responses from patient or caregiver participants. Thematic analysis was used for items identified in the qualitative research. Candidate domains were reviewed and the most representative and informative were chosen through virtual consensus meetings and surveys. Candidate domains were compared between sources and classified into the OMERACT core areas.

Results: The scoping review identified 260 observational studies published from 1978 -2020.  There were 41 participants in the qualitative research (Table 1). Over 300 domains were identified (SR = 220, FG = 79, ODB = 28). These were thematically grouped and reduced to 36 final domains covering each of the OMERACT core areas (Table 2). Most domains map to life impact and pathophysiological manifestations. Twenty-five of the final candidate domains were identified by the scoping review and twenty-two by the qualitative research with 11 items overlapping between the two sources (Figure 1).

Conclusion: A comprehensive and representative preliminary list of domains has been generated for the core domain set for CNO & SAPHO outcome measurement.  The next steps include prioritizing these domains through four rounds of Delphi Survey to determine the final lists of core domains, circumstance-dependent core domains, and domains for future consideration. The core domain set will be determined through future work and used to guide future clinical research.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: M. Oliver: None; s. Thornhill: None; B. Shea: None; J. Akikusa: Pfizer, 1; C. Hedrich: Merck, 5; P. Mease: AbbVie, 2, 5, Aclaris Therapeutics, 2, 5, Aclyrin, 2, 5, Amgen, 2, 5, Boehringer Ingelheim, 2, 5, Bristol Myers Squibb, 2, 5, CorEvitas, 2, 5, Galápagos, 2, 5, Gilead, 2, 5, Inmagene, 2, 5, Janssen, 2, 5, Lilly, 2, 5, MoonLake Immunotherapeutics, 2, 5, Novartis, 2, 5, Pfizer Inc, 2, 5, Sun Pharma, 2, 5, UCB, 2, 5; Y. Zhao: Bristol-Myers Squibb(BMS), 5.

To cite this abstract in AMA style:

Oliver M, Thornhill s, Shea B, Akikusa J, Hedrich C, Mease P, Zhao Y. Comparing Domains Reported by Patients and Other Collaborators in CNO and SAPHO: A Qualitative Study and Scoping Review Using the OMERACT Process [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/comparing-domains-reported-by-patients-and-other-collaborators-in-cno-and-sapho-a-qualitative-study-and-scoping-review-using-the-omeract-process/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparing-domains-reported-by-patients-and-other-collaborators-in-cno-and-sapho-a-qualitative-study-and-scoping-review-using-the-omeract-process/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology